Epitalon

Epithalon, Epithalone, AEDG peptide, Ala-Glu-Asp-Gly, synthetic analog of Epithalamin (pineal extract)

Checked Oct 28, 2026

The short answer

No human evidence yet for longevity and anti-aging in healthy adults

Grade D for longevity: no human trial has tested lifespan or aging outcomes with this peptide, and the famous mortality results came from a pineal extract, not the synthetic peptide.

Approved?: Not approved for any use.
Safety: C, thinly characterized: The few small human studies reported no serious adverse events, and FDA found no adverse-event reports through December 2025, which is missing data rather than proof of safety.

The full answer: what it is for, the dose, the units

What people take it for: People take it for longevity and sleep, on the idea that this four-amino-acid peptide mimics a hormone-like signal from the pineal gland that fades with age.

Does it work for longevity and anti-aging in healthy adults? D, no human evidence yet. Result: not tested in humans.

Grade D for longevity: no human trial has tested lifespan or aging outcomes with this peptide, and the famous mortality results came from a pineal extract, not the synthetic peptide. The only randomized human study, 40 women, raised a urinary melatonin marker.

No approval for any use.

Highest evidence for any use: B for raising a urinary melatonin marker in women with low output (one small randomized study).

Safety: C, thinly characterized. The few small human studies reported no serious adverse events, and FDA found no adverse-event reports through December 2025, which is missing data rather than proof of safety.

Do not use if: No formal contraindication list exists because it has never gone through proper drug development.

Could it be placebo? No controlled trial measured sleep, mood or aging outcomes, so a placebo effect cannot be ruled out for anything users report feeling.

The dose people use, and the units to draw

No named source gives an injected dose. The one randomized human study used about 0.5 mg a day as a sublingual spray for 20 days, and Huberman Lab and Dr. Abud Bakri both discuss epitalon without a dose.

Source	Dose	How often and how	Who it was for	Link
Ivko et al. 2021 (randomized, placebo-controlled study, as described by FDA)	About 0.5 mg a day of the peptide (1 mL of spray corresponded to 0.5 mg a day)	Sublingual spray, 3 sprays twice a day for 20 days, versus saline spray; blinding not specified	40 women aged 40 to 50, mostly night-shift workers, with low urinary 6-sulfatoxymelatonin	FDA briefing document, section on the medical conditions epitalon has been used to treat (Ivko et al. 2021 bullet) and the clinical safety section
Huberman Lab, Apr 1, 2024 (Andrew Huberman)	No dose stated	Says the case rests largely on animal data and that no clinical trials point directly to taking a given amount of epitalon several times a week to extend life	General discussion of peptides for longevity	01:06:12 to 01:11:56 (auto-transcript at podscripts.co, verify by ear)
Huberman Lab, Jun 1, 2026 (Dr. Abud Bakri)	No dose stated	Describes the Khavinson longevity study of the pineal extract epithalamin plus thymalin as a 10 or 20 day course per year, and no epitalon dose	Discussion of Khavinson's nursing-home study (extracts, not the synthetic peptide)	01:24:33 (auto-transcript at podscripts.co, verify by ear)

No named non-seller source gives an injected epitalon dose. The flat daily doses printed on the site before come from seller web pages that FDA's own briefing cites, or had no named source. The retinitis pigmentosa injection series (Khavinson 2002) states no dose in its abstract. Examine.com could not be opened (rate limited).

Reported by the named source, never prescribed by us.

How many units do I draw?

On a U-100 insulin syringe, units = 100 x dose (mg) / (vial mg / water mL). Enter your vial size, the water you add and the dose in the calculator and it does the arithmetic. Open the dose calculator

Why it might work

Subcutaneous or intranasal administration → systemic distribution
Epitalon is a synthetic tetrapeptide (
Telomerase (TERT) expression upregulation in somatic cells
In-vitro work by Khavinson's group and
Telomere length maintenance → reduced replicative senescence
Longer telomeres in dividing cells del
Pineal / melatonin pathway interaction → circadian and antioxidant effects
Epitalon is also proposed to restore p
Assumed downstream outcome: slowed aging biomarkers
The ultimate claim

Assumed pathway, not shown in people.

Assumed mechanism: Epitalon is proposed to act as a peptide bioregulator that enters cells and influences gene expression, with the headline effect being upregulation of telomerase (hTERT) leading to telomere elongation. Secondary assumed actions include stimulating pineal melatonin synthesis / normalizing circadian rhythm, antioxidant effects, and modulation of immune (IL-2, thymocyte) signaling. Reviewers stress the precise mechanism remains unverified after ~25 years; none of this is established drug pharmacology.

The trials, claim by claim

In vitro, Epitalon activates telomerase in human somatic cells and elongates telomeres, allowing cultured fibroblasts to divide beyond the typical Hayflick limit (e.g., past passage 44 vs ~34 in controls).

Result: not tested in humans

Reproducible in cell-culture and a 2025 multi-cell-line replication, but this is in-vitro/mechanistic evidence, not a clinical outcome. Telomere elongation in a dish does not establish lifespan or healthspan benefit in people.

Al-Dulaimi et al., Biogerontology 2025, epitalon and telomere length in human cell lines (also Khavinson 2003, PMID 12937682)

Decades of rodent and Drosophila studies report extended mean/maximum lifespan, reduced spontaneous tumor incidence, and fewer chromosomal aberrations.

Result: not tested in humans

Consistent but animal-only, and overwhelmingly produced by one research group (Khavinson/Anisimov). Strong animal data does not raise the human evidence grade.

Anisimov et al., Biogerontology 2003, Epitalon, biomarkers of aging, life span and tumor incidence in SHR mice (also Kossoy 2006, PMID 16634527)

Human use of the SYNTHETIC peptide is limited to small studies from one group: a retinitis pigmentosa injection series (~162 patients, no blinding or randomization reported, not re-verified) and a 2021 sublingual melatonin study (75 women assessed, 40 low-melatonin-output women randomized to placebo or peptide for 20 days, blinding not reported).

Result: worked

The 2021 study is described by FDA as randomized and placebo-controlled, which meets the definition of a human RCT. It was small, short (20 days), from the originating group, with a melatonin endpoint only and no reported blinding. It says nothing about aging or longevity outcomes, and the injected use is not covered by it. The retinitis pigmentosa series is observational.

FDA briefing document, epitalon, July 2026 (describes the 2021 sublingual study)

The famous 'reduced all-cause mortality in elderly' results came from EPITHALAMIN (bovine pineal extract), not synthetic Epitalon.

Result: not tested in humans

This is the single biggest honesty issue: the Korkushko follow-up (79 coronary patients, randomized to epithalamin courses or usual care, with lower mortality in the treated group) tested the extract preparation, then the benefit gets quietly transferred to the injectable tetrapeptide in marketing. Different compound, open comparison, single research group.

Korkushko et al., Bull Exp Biol Med 2011, epithalamin in elderly coronary patients, 15-year follow-up

A 2023 case report showed a ~7.9-year drop in 'biological age' and a small telomere increase after Epitalon cycles.

Result: not tested in humans

n=1, no control, no blinding, and the patient simultaneously received therapeutic plasma exchange, umbilical-cord stem cells/exosomes, and daily Semax, the authors themselves admit causal attribution to Epitalon is unknown. Essentially uninterpretable for this peptide.

Restorative Medicine case report (biological age)

Status

No FDA approval for any indication, and no trial registered on ClinicalTrials.gov (checked October 12 2026).

Verified absence, there is no U.S. regulatory authorization and no registered controlled trial of Epitalon. (The related extract epithalamin has some Russia-only clinical use.)

ClinicalTrials.gov search: epitalon / epithalon

Status

FDA found no adverse-event reports for epitalon in its safety databases through December 2025, and no human study of subcutaneous epitalon for insomnia.

Absence of data in FDA's July 2026 review. A negative search is not safety evidence.

FDA briefing document, epitalon, July 2026

An independent 2025 lab study found epitalon lengthened telomeres in breast cancer cell lines through ALT, as well as in normal cells through telomerase.

Result: not tested in humans

Cell lines only. An erratum was issued in November 2025.

Al-Dulaimi et al., Biogerontology 2025

Risks and the label warnings

Adverse events

Across the small human studies reported, no serious adverse events were documented, the retinitis pigmentosa series explicitly noted no side effects. Community reports cluster on minor, short-lived issues: injection-site redness, brief lethargy in the first few doses, mild headache/dizziness, and occasional first-week sleep changes. None of this comes from rigorous safety monitoring.

Contraindications

No formal contraindication list exists because it has never gone through proper drug development. Reasonable caution would steer anyone with an active or recent malignancy, or significant cancer risk, away until the telomerase-and-cancer question is answered. Pregnancy, breastfeeding, and pediatric use are uncharacterized and should be treated as off-limits. As an injectable gray-market peptide, sourcing/sterility and reconstitution hygiene are practical risks independent of the molecule itself.

Theoretical concerns

The central theoretical concern is mechanistic: anything that lengthens telomeres could, in principle, support pre-malignant or malignant cells. A 2025 independent lab study found epitalon lengthened telomeres in breast cancer cell lines (through the ALT pathway) as well as in normal cells. That is cell-line data, not a human signal. Proponents counter with the animal anti-tumor data, but that data is single-group and species-limited, and the cancer-risk question in humans is simply unresolved. There is no genotoxicity or carcinogenicity dataset in humans to lean on either way.

What nobody knows yet

Long-term human safety is effectively unknown, there is no multi-year, controlled follow-up on the synthetic peptide. Pharmacokinetics (half-life, distribution, metabolism) are not formally characterized in humans. There are no data on drug interactions, no defined therapeutic window, and no independent verification of purity/identity in gray-market product. The gap between 'no reported harm in tiny studies' and 'demonstrated safe' is very wide here.

What else could explain the result

Attribution is genuinely hard with this compound. Users almost always run it inside longevity stacks (other peptides like Semax/Selank, GH secretagogues, NAD+ precursors, metformin/rapamycin, melatonin) and concurrently optimize sleep, training, and diet. The headline case report layered Epitalon on top of plasma exchange and stem cells. Any 'biological age' or telomere readout is also lab- and method-dependent and noisy, so improvements are easily mis-credited to Epitalon.

Is the vial what it says?

Cross-checked against: an independent Cognitive Vitality (Alzheimer's Drug Discovery Foundation) assessment, two 2024-2025 peer-reviewed PMC review articles, the original Khavinson-group telomerase/lifespan literature, the n=1 restorative-medicine case report, Wikipedia (flagged for over-reliance on primary sources), and a ClinicalTrials.gov / FDA absence check. The epithalamin-vs-Epitalon attribution issue and the lack of registered RCTs were confirmed across multiple independent sources.

Half-life and storage

Half-life: Not formally characterized in humans. As a small linear tetrapeptide it is expected to be rapidly degraded by peptidases (a short circulating half-life on the order of minutes is plausible), but published reference charts list its half-life as 'not well characterized / limited data,' so any specific number is an estimate, not a measured value.

Once mixed: Supplied as a lyophilized powder; reconstitute with bacteriostatic (not sterile-only) water for multi-day use. Sensitive to heat, light, and agitation, swirl rather than shake. Store the vial refrigerated; keep reconstituted solution cold and use within a few weeks. Powder is more stable than solution. Identity and purity of gray-market product are not guaranteed, which is a meaningful real-world handling risk.

What I noticed, and what people report

What people report

Volume of reports: faint. Little real-world record, or mostly noise.

Moderate chatter in longevity and peptide communities. Epitalon is a well-known 'name brand' in anti-aging circles, but the volume of substantive, detailed first-hand reports is thinner than for popular recovery or GLP-1 peptides, and a large share of visible content is vendor or affiliate material rather than disinterested user experience.

Inconsistent and mostly soft. The most repeated subjective report is better/deeper sleep during a cycle; beyond that, 'feel younger / more energy' is vague and variable. The core selling point, actually living longer or measurably reversing aging, is something individual users cannot perceive, so there is no consistent real-world outcome to point to, only proxy lab numbers that are easy to misattribute.

Low-to-moderate. Sentiment is heavily shaped by vendors and longevity influencers with an incentive to sell, and the strongest-sounding 'human evidence' people cite usually turns out to be the epithalamin extract studies or the confounded n=1 case report. Discounting affiliate sources leaves a modest, mostly-subjective anecdote base. Treat as hypothesis-generating only.

The most common anecdote is improved sleep depth and more vivid dreams during a short cycle, often the first thing users mention (anecdote, not proof).
Many report a vague 'feel younger / more recovered / more energy' sense that is hard to pin to anything measurable.
A subset of users say they noticed nothing at all and view the longevity claims as unfalsifiable or placebo, especially given the cost and injection burden.
Practitioner and biohacker communities tend to treat it as a 'maybe it helps, low felt downside' annual ritual rather than something with a clear, reproducible effect, and frequently can't separate it from the rest of their stack.

Reports are anecdote, not proof.

Can you tell if it is working?

Partly trackable

The only non-blood readout worth keeping is a urinary melatonin-metabolite (aMT6s) check, and even that is a mechanism proxy, not proof the peptide works; wearable sleep tracking was cut because for epitalon it measures expectation and staging noise, not efficacy.

Bloodwork

No blood proxy

Nothing on a routine panel confirms this one. Anyone who says otherwise is guessing.

Epitalon (Ala-Glu-Asp-Gly) is a pineal tetrapeptide bioregulator; its claimed actions are hTERT/telomerase upregulation with telomere elongation and restoration of nocturnal melatonin rhythm. None of those map onto a routine LabCorp/Quest analyte, and it has no known dose-dependent effect on any standard CBC, CMP, lipid, or hormone panel value that would predictably rise or fall as it works.

Read this before you spend on labs

You cannot prove epitalon is working with routine bloodwork. Its two mechanistic readouts are both off the standard menu: telomerase activity and telomere length are research assays (qPCR/flow-FISH, demonstrated mainly in cultured human cells, not orderable at LabCorp/Quest as validated efficacy tests), and leukocyte telomere length carries large inter-person variance and drifts over years, so no individual can attribute a change to a short peptide course. The one semi-objective human signal, a shift in nocturnal melatonin rhythm, is not a routine panel and rests on weak, single-lab (Russian) evidence for the related preparation epithalamin rather than the tetrapeptide itself. The benefits users actually chase, sleep depth, vitality, and slowed aging, are subjective or unmeasurable on any standard panel. Do not order labs to confirm this one; there is no honest blood proxy.

Other ways to track it

UrineIndirect / noisy

Urinary 6-sulfatoxymelatonin (aMT6s), overnight or first-morning collection, orderable through specialty labs as a non-invasive index of endogenous melatonin output

If the peptide's one semi-objective claimed action holds, you would see overnight aMT6s rise versus your own pre-cycle baseline, indicating higher nocturnal melatonin output. This is strictly a MECHANISM marker: it can show melatonin moved, but it cannot prove the marketed longevity, telomere, or sleep-quality benefit, and the human evidence that epitalon raises melatonin at all is weak, single-lab, and unblinded. A rise is consistent with the mechanism, not confirmation the compound 'works.'

6-sulfatoxymelatonin is the standard, validated non-blood proxy for endogenous melatonin production, which is the specific pathway epitalon is claimed to restore; it directly tests the single mechanism the literature describes, without relying on subjective report.

Take 1-2 baseline overnight/first-morning collections before starting to average out night-to-night noise, then repeat mid-cycle and at cycle end, holding collection time, light exposure, and conditions constant.How to do it right

Bottom line

Beyond blood, there is no validated way to prove epitalon works. Only one honest proxy survives: urinary aMT6s, which objectively indexes the claimed mechanism (nocturnal melatonin output) but is not an efficacy endpoint and rests on weak, single-lab, unblinded human data, so even a clear rise cannot confirm the marketed longevity/telomere benefit. Interpret any positive signal as mechanism-consistent at best, only against a solid personal baseline using multiple collections. Wearable sleep tracking was removed: for this compound it has no controlled human trials, the reported effect is subjective and strongly placebo-prone, consumer sleep staging is unreliable, and it captures expectation and noise rather than the compound's action.

Logging baseline vs retest is the whole game. The Truth Tracker is our free log for bloodwork, DEXA, genetics, and wearable data, bring your own numbers.

How to track it

History

First documented human use: No trial of synthetic Epitalon (AEDG) is registered on ClinicalTrials.gov. The only randomized placebo-controlled human study found is a small 2021 sublingual study from the originating Russian group (40 women with low melatonin output given placebo or peptide for 20 days, blinding not reported). The earliest documented human use traces to Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology in the late 1990s-2000s (e.g., a parabulbar-injection retinitis pigmentosa series), mostly non-blinded and non-randomized, and all from a single research group. The widely-cited "elderly mortality reduction" results (the Korkushko follow-up of 79 coronary patients) used EPITHALAMIN, the bovine pineal extract, not the synthetic Epitalon peptide most people inject today.

Update: an FDA advisory panel voted in favor of this one on July 23-24, 2026

The FDA's Pharmacy Compounding Advisory Committee voted to recommend adding this to the 503A Bulks List, meaning compounding pharmacies could legally prepare it. The vote: 7 in favor; published reports differ on the no count (4 or 5), and FDA has not posted a tally. Now read the fine print, because it matters more than the headline. The vote is advisory and changes nothing today: FDA still has to go through formal rulemaking, which can take a year, and it has overruled its own panels before. As of November 2, 2026, FDA has not published a proposed rule and this is not on the 503A Bulks List. Separately, HHS published a draft enforcement-discretion policy in the Federal Register on October 30 (docket HHS-OASH-2026-0496) that says HHS does not intend to act against pharmacies that compound certain single-ingredient peptides under conditions. The notice itself says compounded drugs are not FDA-approved. That is enforcement discretion: a draft, not a rule, not approval, and not a ruling that the compound works, and HHS can revise it. The list of named peptides and routes sits in an appendix we could not open, so which peptides it names is as press and law firms report it, not as we read it. FDA's own scientists recommended AGAINST adding it, citing thin human evidence and unassessed immunogenicity risk, and the committee voted the other way. That committee is also not neutral: it was reconstituted with recent appointees, and several work at or run clinics that sell peptide treatments. And none of this is a finding that the compound works. A compounding-eligibility vote is not drug approval, and it is not evidence. Our grade here is unchanged, because the evidence did not change.

Vote tallies as reported by the press (STAT, McDermott Will and Schulte); FDA has not posted tallies, minutes or a transcript, and its meeting materials are on its meeting page. Rechecked November 2, 2026 against FDA and Federal Register primary pages: FDA has published no proposed rule, docket FDA-2025-N-6895 closed July 22, 2026, and HHS published a draft enforcement-discretion policy in the Federal Register on October 30, 2026 (docket HHS-OASH-2026-0496). Nothing here is final, so check the current policy and rule before acting.. FDA, PCAC meeting, July 23-24 2026

1970sKhavinson and colleagues isolate 'epithalamin,' a peptide extract from bovine pineal gland, at the St. Petersburg (Leningrad) gerontology institute.
1980s-1990sSynthetic tetrapeptide Ala-Glu-Asp-Gly (Epitalon/Epithalon) developed as a defined-sequence analog of the extract's active fraction.
2003Bulletin of Experimental Biology and Medicine reports Epitalon induces telomerase activity in human somatic cells in culture.
2004Follow-up reports describe Epitalon-treated human fibroblasts dividing beyond the Hayflick limit; rodent lifespan/anti-tumor papers accumulate.
2000sSmall human use of the synthetic peptide (a retinitis pigmentosa series, then a sublingual circadian/melatonin study published in 2021), all from the same group.
2017AEDG reported as detectable in vivo; mechanistic gene-expression / epigenetic work continues.
2025Brunel University London reports epitalon lengthens telomeres in normal cells (telomerase) and in breast cancer cell lines (ALT); erratum Nov 2025.
Jul 24 2026PCAC recommends epitalon for the 503A list (7 in favor; published reports differ on the no count, 4 or 5, and FDA has not posted a tally). FDA's briefing weighed against it and found no adverse-event reports. Advisory only: no FDA proposed rule as of Oct 12 2026.

All sources

PMC review: Overview of Epitalon, a bioactive pineal tetrapeptide (2024)(Peer-reviewed overview; notes mechanism still unverified, only two small human studies, and that toxicity/safety studies are still needed.)
Cognitive Vitality (Alzheimer's Drug Discovery Foundation): Epithalamin & Epithalon assessment(Independent assessment; flags single-group dominance, lack of blinding/randomization/replication, and limited long-term safety data.)
Al-Dulaimi et al., Biogerontology 2025, epitalon and telomere length in human cell lines(Primary in-vitro telomerase/telomere literature (Khavinson group + 2025 replication).)
Korkushko et al., Bull Exp Biol Med 2011, epithalamin in elderly coronary patients, 15-year follow-up(Source of the famous mortality-reduction numbers, note these used the pineal EXTRACT, not synthetic Epitalon.)
FDA briefing document, epitalon, July 23-24 2026 PCAC(Primary source for the insomnia review, the description of the 2021 sublingual study, and the absence of adverse-event reports through December 2025.)
Restorative Medicine: n=1 biological-age case report (2023)(Single confounded case (plasma exchange + stem cells + Semax co-administered); authors admit causation is unknown.)
ClinicalTrials.gov search: epitalon / epithalon(Verifies no registered controlled trial; no FDA approval for any indication.)
Ivko OM, Linkova NS, Ilina AR, Sharova AA, Ruzhak GA. Adv Gerontol 2021;11(1):53-58, as summarized in the FDA briefing document for the July 23-24, 2026 Pharmacy Compounding Advisory Committee (epitalon)(dose table)
Huberman Lab, 'Benefits & Risks of Peptide Therapeutics for Physical & Mental Health', Apr 1, 2024, chapter 01:06:12, remark at about 01:11:56(dose table)
Huberman Lab, 'Peptides: The Science, Uses & Safety', Dr. Abud Bakri, Jun 1, 2026, chapter 01:19:55, about 01:24:33 to 01:24:48(dose table)

Not medical advice. Grades reflect the evidence as of the date above and will change as data arrives. Reports from users are anecdote, not proof. Talk to a licensed clinician before you act on anything here.